Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

K2M Inc.

This article was originally published in Start Up

Executive Summary

K2M has implemented eight silos of research in spine, each essentially acting as its own independent technology incubator, dedicated to developing spine medical technologies for specific indications.

You may also be interested in...



Welsh Carson Sits in K2M Driver's Seat

With the backing of the private equity powerhouse Welsh Carson, K2M will look to grow beyond its historical niche in complex spinal cases, though it will have to do so without any financial ties to the surgeons who once owned part of the company.

Welsh Carson Sits in K2M Driver's Seat

With the backing of the private equity powerhouse Welsh Carson, K2M will look to grow beyond its historical niche in complex spinal cases, though it will have to do so without any financial ties to the surgeons who once owned part of the company.

Preserving Spinal Motion, Preserving Options

Dynamic stabilization may sound like an oxymoron, but the concept is driving compound annual growth of more than 50% over the next decade in a new segment of the spine industry. The US market for spinal motion preserving and nonfusion products was worth approximately $186 million in 2004, and is projected to reach more than $1.5 billion in the year 2009, according to "US Markets for Spinal Motion Preserving Devices," a report just published by Windhover/Medtech Insight.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037450

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel